Agenus Inc. (AGEN) CTO Alex Duncan Sells 6,546 Shares

Agenus Inc. (NASDAQ:AGEN) CTO Alex Duncan sold 6,546 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $3.46, for a total transaction of $22,649.16. Following the sale, the chief technology officer now directly owns 27,572 shares in the company, valued at approximately $95,399.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Agenus Inc. (NASDAQ AGEN) traded up $0.01 on Thursday, reaching $3.52. 782,618 shares of the company’s stock were exchanged, compared to its average volume of 1,184,884. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of -2.39. Agenus Inc. has a twelve month low of $3.20 and a twelve month high of $5.45.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.37). The company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $5.91 million. Agenus’s revenue was down 24.4% on a year-over-year basis. sell-side analysts predict that Agenus Inc. will post -1.19 EPS for the current year.

A number of analysts have commented on the stock. BidaskClub cut shares of Agenus from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. Zacks Investment Research cut shares of Agenus from a “buy” rating to a “hold” rating in a research report on Friday, August 25th. Finally, ValuEngine raised shares of Agenus from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Agenus has a consensus rating of “Hold” and a consensus price target of $5.81.

Hedge funds have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co. NY boosted its position in shares of Agenus by 12.2% during the 1st quarter. Metropolitan Life Insurance Co. NY now owns 55,920 shares of the biotechnology company’s stock worth $211,000 after purchasing an additional 6,101 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of Agenus by 15.1% during the 2nd quarter. Alliancebernstein L.P. now owns 144,700 shares of the biotechnology company’s stock worth $566,000 after purchasing an additional 19,000 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Agenus by 11.4% during the 2nd quarter. Wells Fargo & Company MN now owns 520,142 shares of the biotechnology company’s stock worth $2,033,000 after purchasing an additional 53,343 shares in the last quarter. Northern Trust Corp boosted its position in shares of Agenus by 4.1% during the 2nd quarter. Northern Trust Corp now owns 941,631 shares of the biotechnology company’s stock worth $3,682,000 after purchasing an additional 37,239 shares in the last quarter. Finally, Artal Group S.A. boosted its position in shares of Agenus by 25.0% during the 3rd quarter. Artal Group S.A. now owns 2,500,000 shares of the biotechnology company’s stock worth $11,025,000 after purchasing an additional 500,000 shares in the last quarter. 37.90% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Agenus Inc. (AGEN) CTO Alex Duncan Sells 6,546 Shares” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/14/agenus-inc-agen-cto-alex-duncan-sells-6546-shares.html.

About Agenus

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply